September 23, 2022

Cellular Goods launches Rejuvenating Skincare products containing PureForm CBD

PureForm Global, Inc. (“PureForm Global”), a California-based biotechnology company focused on the research, development, and commercialisation of bioidentical lab-made cannabinoids, is pleased to announce that Cellular Goods (LSE: CBX), a UK-based wellness company providing premium consumer products formulated with lab-produced cannabinoids, has launched its first products formulated with PureForm CBD.

PureForm Global’s proprietary, synthetically produced cannabidiol (“CBD”) has been used in the formulation of Cellular Goods’ new Rejuvenating Skincare products, released on 21 September 2022 as part of its ‘Look Better’ (skincare) range. The three products containing PureForm Global’s ultra-pure CBD include Cellular Goods’ Rejuvenating Night Cream, SPF 25 Rejuvenating Day Cream and Rejuvenating Day Mousse. The products contain PureForm CBD and focus on fighting the effects of inflammation, a root cause of skin ageing.

PureForm Global develops and manufactures bioidentical cannabinoids for use in the consumer and pharmaceutical industries and produce CBD at commercial scale in facilities in the US and UK that are wholly FDA and Current Good Manufacturing Practice (cGMP) compliant. PureForm CBD has received certification from the Clean Label Project, an independent non-profit that is championing transparency in consumer product labelling. The Clean Label Project has awarded PureForm with its THC Free Award, Pesticide Free Certification and Purity award.

Anna Chokina, Cellular Goods’ chief executive, said: “PureForm’s lab-based production method is faster, more efficient and has a greatly reduced carbon footprint compared to field-based production methods of CBD. Their UK manufacturing capabilities have the added benefit of a short supply chain, ensuring consistent supply of CBD in commercial quantities. We are delighted with the results of our partnership so far and look forward to a continuing relationship as we deliver high-quality products to our customers.”

“Anna and her team make clear to their partners that the quality and purity of their products are non-negotiable. PureForm Global is proud to supply Cellular Goods with CBD for its wellness products, and we share their commitment to premium quality,” said Richard Nanula, PureForm’s CEO.

March 8, 2022

PureForm Global has been awarded its first Patent from the U.S. Patent and Trademark Office for its process for synthesizing CBD

The patented process (U.S. Patent 11,267,774) uses as its primary starting material a compound derived from citrus terpenes. It is used to produce CBD that is bioidentical to the compound found in cannabis and hemp plants, except without the dangerous impurities found in those plant sources.
"This patent represents an important proof of concept that PureForm intends to build upon in development of dozens of future cannabinoid compounds. We believe companies with valuable brands that want to bring the benefits of cannabinoids to their customers will only want consistent, pure, materials that are the same every time for their high-volume production lines,” said Damian Peters, co-founder of PureForm. “I would like to congratulate the co-inventors, Marc Bencivenga, Matthew Forster, Paul Herrington, Paul Jass, Surendra Singh, and Todd Zahn for their important work in helping PureForm achieve this first milestone of many.”

December 7, 2021

PureForm CBD achieves Clean Label Certification in three areas

PureForm CBD has been certified by Clean Label Project, an independent product quality certification company. We have attained the Pesticide Free Certification, Purity Award and THC Free Award. There are only a few CBD brands that have passed these tests, and PureForm CBD is now the only CBD ingredient with these certifications.

September 8, 2021

Prohibition Partners: The Pharmaceutical Cannabis Report Edition 2

The most common cannabinoids in cannabis plant material are THC and CBD or more specifically, their carboxylated form THCa and CBDa. These cannabinoid acids are transformed e.g. combustion provides the active THC and CBD which are associated with medicinal and recreational utility. However, there are a range of over 100 cannabinoid compounds which are variously referred to as ‘minor cannabinoids’, with biological activity, which have been established, but poorly investigated by researchers.

August 27, 2021

NutraCast: PureForm Global on making CBD from orange peel

As popular and as in demand CBD is, there is a huge chunk of the population who can’t see what the fuss is all about. Why? Because CBD products made from hemp could contain THC, a molecule that will lead to failed drug tests. But there may be an option out there after all. Bioscience company PureForm is leading the effort to make CBD accessible to all, by making CBD from orange peel.

August 9, 2021

PureForm Global Secures European Food Safety Authority Novel Food Validation

PureForm Global Inc, through its UK subsidiary PureForm International Ltd, has become the only UK CBD manufacturer to receive validation from the European Commission and the European Food Safety Authority for its Novel Food application.

March 17, 2021

PureForm Global submits its Novel Food Application for PureForm CBD™

Los Angeles, CA, and London, England, March 17, 2021 – PureForm Global, Inc. (PureForm) announced today they have successfully submitted their detailed dossiers seeking Novel Food and Food Standard Agency (FSA) approval for their company's PureForm CBD™. PureForm’s synthetic cannabinoids are 100% chemically identical to their cannabis-derived counterparts and are manufactured using a proprietary process that produces pure, consistent and stable compounds free from THC, pesticides, and impurities.

“PureForm is the only company that manufactures and sells bulk CBD in the UK and can guarantee there is no THC, even at the 0.0001% level of detection” said Simon Lapthorn, Head of European Sales.

“Consumers want CBD products that they can buy with confidence. The submission of both our Novel Food and FSA applications gives them just that, when they buy products with PureForm CBD™ inside,” said Steve Miller, COO of PureForm. “Independent tests have consistently demonstrated that many products have misleading labelling, THC and dangerous impurities so PureForm have always supported the need for all CBD products to pass the most stringent of safety standards.”

CBD was placed on the Novel Foods Catalogue in 2020, meaning that the ingredient requires preauthorization prior to it being in any product that is manufactured to be ingested. Most countries in Europe stringently enforce Novel Food rulings, meaning that many countries, including the UK, have confirmed that non-compliant products will be removed from shelves on 31 March 2021.

PureForm is the CBD of choice for a range of products already sold in over 600 outlets throughout the United States. These include topical patches and creams, tinctures, capsules, gummies, bars, and beverages.

About PureForm Global, Inc.
Headquartered in Los Angeles, California, PureForm is a biotechnology company focused on the research, development, and commercialization of synthesized CBD and other cannabinoids. PureForm produces CBD at commercial scale in cGMP and FDA compliant facilities in the US and UK. It was
founded in 2016 with a commitment to bringing pure, consistent, cannabinoids to market economically and at commercial scale in service to the world's most quality conscious brands. To learn more about PureForm CBD™ or our other initiatives, please visit www.pureformglobal.com

Forward-Looking Information
Certain statements in this announcement are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, many of which, by their nature, are inherently uncertain and outside of the Company's control and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements

February 25, 2021

Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs

NAPLES, Fla., Feb. 25, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has launched a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc. ("PureForm"), a biotechnology company focused on the research, development and commercialization of synthesized CBD and other cannabinoids, for treating pain and inflammation resulting from cancer treatments. The agreement allows two leading edge companies to bring their focus and resources to bear on superior products to serve unmet medical needs.

September 2, 2020

Biosportart partners with U.S. cannabinoid biotech PureForm Global to produce synthesized CBD products for UK athletes

LONDON: Biosportart, a sports-focused CBD startup, has signed a comprehensive supply agreement with U.S. cannabinoid biotech PureForm Global to launch the first synthesized CBD products for athletes in the UK.